Author

S. J. Baker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:DNA methylation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:clustering· 1

Frequent Co-Authors

B. A. Orr· 2 shared J. Zhang· 2 shared K. Xu· 2 shared A. A. Shelat· 1 shared A. Broniscer· 1 shared A. Donson· 1 shared A. Gajjar· 1 shared A. K. Aggarwal· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. A. Orr

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response

C. He, K. Xu, X. Zhu, P. S. Dunphy, B. Gudenas, W. Lin, N. Twarog, L. D. Hover, C.-H. Kwon, L. H. Kasper, J. Zhang, X. Li, J. Dalton, B. Jonchere, K. S. Mercer, , S. J. Baker

The paper establishes patient-derived orthotopic xenograft models and cell lines from pediatric high-grade glioma that replicate histopathology, molecular signatures, and drug response, providing a resource for research.

bioRxiv · Dec 6, 2020 · PreprintCancer Biology

Mechanism of action of rigosertib does not involve tubulin binding

S. J. Baker, S. C. Cosenza, S. Athuluri-Divakar, M. V. R. Reddy, R. Vasquez-Del Carpio, R. Jain, A. K. Aggarwal, E. P. Reddy

This paper investigates the mechanism of action of rigosertib and finds that it does not involve tubulin binding, as clinical grade rigosertib lacks the impurity responsible for this activity.

bioRxiv · Dec 12, 2019 · PreprintCancer Biology

Comprehensive molecular characterization of pediatric treatment-induced high-grade glioma: A distinct entity despite disparate etiologies with defining molecular characteristics and potential therapeutic targets

J. DeSisto, J. T. Lucas, K. Xu, A. Donson, T. Lin, B. Sanford, Q. T. Tran, D. Hedges, C.-Y. Hsu, G. T. Armstrong, M. Arnold, S. Bhatia, P. Flannery, R. Lemma, L. Hardie, , A. L. Green

This study characterizes treatment-induced high-grade gliomas (TIHGGs) through molecular profiling, identifying distinct subgroups and potential therapeutic targets.

bioRxiv · Oct 29, 2019 · PreprintCancer Biology